The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid shifting dynamics in the biotech sector, Moderna, Inc. has received an average analyst rating of 'Reduce' from 18 brokerages. The 12-month average price target for the company's stock has been set at $38.27, signaling significant downside risk according to consensus estimates. Furthermore, persistent insider selling by executives and a spike in bearish options trading activity have added to the negative momentum surrounding the instrument.
These headwinds persist despite Moderna securing a European Commission contract for its RSV vaccine, as the market remains focused on downward revisions from major institutions like Morgan Stanley. Per market data, Moderna's performance has lagged behind broader biotech benchmarks such as the Nasdaq Biotechnology Index, as investors pivot toward companies with more diversified revenue streams and stronger balance sheets.
Looking ahead, market participants are closely monitoring upcoming macroeconomic catalysts, including speeches by Fed officials Waller and Bowman in July 2026, which could impact high-growth sectors. While current price levels are unavailable for this snapshot, the stock's trajectory remains heavily influenced by whether it can stabilize against the backdrop of institutional downgrades and executive share liquidations.